harvester schreef op 12 mei 2019 22:40:
Langzaam maar zeker wordt de naam Galapagos en het product Filgotinib bekender bij biotech investors, mede door beschouwingen als die van Motley fool van 12 mei:
de kop:Is It Finally Time to Buy Gilead Sciences?
[Motley Fool]
Todd Campbell, The Motley Fool
,Motley Fool•May 12, 2019
2 fragmenten daarvan:Management also reminded investors that it has a shot of adding another drug to its product lineup soon. Following positive results from phase 3 trials evaluating filgotinib, a selective JAK-inhibitor licensed from Galapagos, the company plans to file for European approval in rheumatoid arthritis later this year. Gilead Sciences aims to meet with the FDA to determine a timeline for a U.S. filing this year, and trials are ongoing that could pave the way for filgotinib's use in other inflammatory disorders, too.
Given Gilead Sciences' financial flexibility, the potential for new product launches in 2020, and arguably bargain-basement share prices, I think patient investors can begin buying shares again.